Efficacy and safety of monoclonal antibody AK111 in the treatment of active ankylosing spondylitis: a randomised, double-blind, placebo-controlled, multicentre phase II clinical study
The humanised monoclonal antibody AK111 was safe and well tolerated in treating AS and showed a good efficacy by improved ASAS 20/ASAS 40 response.
Authors
- Michelle Xia
- Zhanguo Li (ORCID: https://orcid.org/0000-0002-2590-6242)
- Baiyong Li (ORCID: https://orcid.org/0009-0002-2426-9656)
- Yongjun Mei
- Hua Ye (ORCID: https://orcid.org/0000-0002-4608-5594)
- Li Zhang (ORCID: https://orcid.org/0000-0002-2783-2742)
- Jieruo Gu (ORCID: https://orcid.org/0000-0002-8785-0600)
- Yuyan Zheng (ORCID: https://orcid.org/0009-0001-4637-8127)
- Shengyun Liu (ORCID: https://orcid.org/0000-0003-3197-3158)
- Min Yang (ORCID: https://orcid.org/0000-0002-1024-8400)
- Guoqin Wang (ORCID: https://orcid.org/0000-0002-6302-577X)
- Zhimei He
- Feiyan Wu (ORCID: https://orcid.org/0000-0002-3650-9437)
Institutions
- Sun Yat-sen University (CN)
- Peking University (CN)
- The Seventh Affiliated Hospital of Sun Yat-sen University (CN)
- Nanfang Hospital (CN)
- Peking University People's Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2024-12-06
- DOI
- https://doi.org/10.55563/clinexprheumatol/2t27x9
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00